AbbVie

This program is designed to provide access to ABBV-399 (Telisotuzumab Vedotin) prior to approval by the local regulatory agency. Availability will depend on the territory eligibility. A medical doctor must decide whether the patient might potentially benefit from receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Criteria:
The patient suffers from a serious or life-threatening illness or condition
There are no other suitable treatment options
The patient does not qualify for ongoing clinical trials